# Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis

> **NCT05927428** · PHASE2 · RECRUITING · sponsor: **BRIM Biotechnology Inc.** · enrollment: 12 (estimated)

## Conditions studied

- Neurotrophic Keratitis

## Interventions

- **DRUG:** BRM424 Ophthalmic Solution - Dose1
- **DRUG:** BRM424 Ophthalmic Solution - Dose2

## Key facts

- **NCT ID:** NCT05927428
- **Lead sponsor:** BRIM Biotechnology Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2025-08-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05927428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05927428, "Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05927428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*